News & Events

• June 8, 2022
  

  PRO Consortium Announces Publication of Open Access Article

  C-Path’s PRO Consortium is pleased to announce that “Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study” was published online by JTO Clinical and Research Reports on February 16, 2022.  The article reports findings from analyses that used clinical trial data to evaluate the NSCLC-SAQ’s longitudinal measurement properties...
• May 20, 2022
  

  eCOA Consortium and PRO Consortium Announce Publication of Open Access Article

  C-Path’s eCOA Consortium and PRO Consortium are pleased to announce that “Recommendations for the Electronic Migration and Implementation of Clinician-Reported Outcome Assessments in Clinical Trials” was published online by Value in Health on April 2, 2022.  The article presents a framework for planning the migration and implementation of electronic ClinRO assessments, as well as best practice recommendations drawn from applicable practices...
• August 5, 2021
  

  C-Path Appoints Clinical Outcome Assessment Expert as New Executive Director

  Critical Path Institute (C-Path) announced it has named Sonya Eremenco, M.A., as Executive Director of its Patient-Reported Outcome (PRO) Consortium. Eremenco joined C-Path in 2016 as Associate Director of the PRO Consortium and was promoted to Director in January 2021. In addition to her leadership roles with the PRO Consortium, she also served as Acting Director of the ePRO Consortium from September 2018 to May 2021.

• June 24, 2021
  

  Clinical Technology Expert and Experienced Neuroscientist Join C-Path in Executive Director Roles

  Scottie Kern and Dr. Terina N. Martínez Will Both Serve in Dual Positions

  TUCSON, Ariz., June 24, 2021 — Critical Path Institute (C-Path) today announced it has named Scottie Kern, as both Executive Director of the Electronic Patient-Reported Outcome (ePRO) Consortium and Associate Director of the Patient-Reported Outcome (PRO) Consortium and Terina N. Martínez, Ph.D., as Executive Director of both the Duchenne Regulatory Science Consortium (D-RSC) and Critical Path to Therapeutics for the Ataxias (CPTA).

• March 9, 2021
  

  C-Path Receives FDA Qualification for the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C)

  TUCSON, Ariz., March 9, 2021 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA). The DIBSS-C was developed by the PRO Consortium’s Irritable Bowel Syndrome (IBS) Working Group to support symptom-based efficacy endpoints in clinical trials for products intended to treat constipation-predominant IBS (IBS-C) in adults. Qualification of the DIBSS-C represents a major milestone for the IBS Working Group and is the PRO Consortium’s fourth clinical outcome assessment (COA) to be qualified through the COA Qualification Program within FDA’s Center for Drug Evaluation and Research.